FDA to review tildrakizumab for active psoriatic arthritis in adults
- FDA accepts supplemental application for tildrakizumab.
- Ilumya aimed at treating adults with active psoriatic arthritis.
- Regulatory review process for Sun Pharma's application underway.
Sun Pharmaceutical Industries has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for tildrakizumab, also known as Ilumya. This application seeks to expand the use of tildrakizumab to treat adults with active psoriatic arthritis, a chronic autoimmune condition that affects the skin and joints. The acceptance of the application marks a significant step in the regulatory process for this potential new indication.
Tildrakizumab is already approved for the treatment of moderate-to-severe plaque psoriasis, and the FDA's review will evaluate its effectiveness and safety for psoriatic arthritis. Psoriatic arthritis can lead to severe joint damage and has a considerable impact on the quality of life of those affected. Sun Pharma is now awaiting a response from the FDA following its standard review timeline.
The decision to expand tildrakizumab's use reflects ongoing efforts to find effective therapies for patients with autoimmune diseases. Should the FDA approve the application, it could offer new treatment options for adults struggling with the symptoms and effects of active psoriatic arthritis.
